Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Tailored vs Standard use of the Combined Oral Contraceptive on Continuation Rates at one year.

Trial Profile

Effect of Tailored vs Standard use of the Combined Oral Contraceptive on Continuation Rates at one year.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ethinylestradiol/levonorgestrel (Primary)
  • Indications Pregnancy
  • Focus Therapeutic Use
  • Acronyms Standard vs Tailored pill taking
  • Most Recent Events

    • 25 Oct 2012 Investigational drug identified as Ethinylestradiol/levonorgestrel as reported by European Clinical Trials Database.
    • 31 May 2012 Additional location (Scotland) added as reported by United Kingdom Clinical Research Network record.
    • 19 Nov 2010 United Kingdom Clinical Research Network reports accrual to date changed from 73% to 85%.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top